The present invention relates to phenyl pyrrole aminoguanidine derivatives of the general formula (I): including tautomeric forms thereof, wherein n is 1, 2 or 3 or a pharmaceutically acceptable salt thereof. The present invention further relates to the use of such phenyl pyrrole aminoguanidine derivatives for the treatment of diseases associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones.